AstraZeneca has returned to recent licensing partner CSPC Pharmaceuticals with $110 million in upfront cash to start work on ...

The offer is the result of a memorandum of understanding signed by both Astellas and Japanese think tank Mitsubishi Research ...

After dropping its only clinical-stage candidate last month, ADC Therapeutics is shutting down a U.K. research site and ...

Exoskeleton developer Wandercraft has raised $75 million in new financing shortly after inking a strategic partnership with ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in all-stock transaction that values the acquired biotech at ...

Merck KGaA has shed more light on the failure of its lupus drug in one cohort of patients, while pointing to secondary ...

Medtronic has landed on a new brand for the planned spinout of its diabetes division, and it didn’t have to look very far. | ...

GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...

Novo Nordisk has planted another seed to fuel the blossoming of its obesity business, inking an $812 million deal with Deep ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...

Vertex is trimming its Rhode Island footprint on the back of a scrapped “cells plus device” program in diabetes, leaving 125 ...